20th May 2019
The global biomedical market is in the midst of a period of stable growth and Catalonia, one of the most dynamic healthcare hubs in the world, is also enjoying this trend. 2018 was a positive year for the Catalan biomedical business fabric, in terms of funding, R&D alliances and advances, and launching new drugs and medical technology.
1st May 2019
Bowmark Capital, the mid-market private equity firm, has agreed to sell CARE Fertility, the UK’s leading fertility clinic group for IVF treatment, to Silverfleet Capital.
29th April 2019
EMV Capital has acquired a controlling stake in Bay Area-based Vortex Biosciences, and a further investment package to accelerate the company’s development.
18th April 2019
Touch Biometrix has received a £2million investment from Deepbridge Capital.
The Series A funding through the Deepbridge Technology Growth Enterprise Investment Scheme (EIS) fund follows initial seed funding of £150,000 last year.
North Wales based Touch Biometrix is developing a new class of fingerprint sensor for application to consumer electronics such as smartphones and laptops.
17th April 2019
Foresight Group has made a £5 million growth capital investment into Northern Ireland’s largest private healthcare business, 352 Medical Group Limited.
10th April 2019
Intermediate Capital Group’s Europe VII Fund has announced it has, in partnership with Mérieux Equity Partners and DOC Generici’s management team, agreed to invest in Doc Generici, one of Italy’s largest independent generic pharmaceutical companies - subject to antitrust approval.
10th April 2019
BGF has successfully exited its minority stake in care service provider, The Good Care Group, alongside all other shareholders. Following a period of significant organic growth, the company has been acquired by Sodexo UK. The Good Care Group offers industry-leading live-in care services which help people live well at home for longer by providing specialist care in the comfort of the home. Founded in 2009 by Fiona Lowry, the group provides care to clients around the UK. The business is leading the way in supporting those with medical conditions including dementia, Parkinson’s, MS and Motor Neurone disease - helping to improve their wellbeing and overall quality of life.
2nd April 2019
Jeremy Curnock Cook, Managing Director of BioScience Managers, comments on the BiA's latest financing figures.
1st April 2019
CroíValve, a medtech start-up providing a safe and effective treatment for tricuspid regurgitation, hasannounced that it has secured €3.2 million in an oversubscribed seed financing round. The round was led by the HBAN (Halo Business Angel Network) MedTech and Irrus Syndicates, alongside Atlantic Bridge University Fund, Enterprise Ireland, SOSV and a group of cardiologists who see the treatment’s transformative potential. The funding will support the continued development of CroíValve’s innovative technology.
26th March 2019
People suffering with communication difficulties are benefitting from a new speech therapy service that has been developed by Caerphilly-based Cog-Neuro Speech Therapy Limited. With a £25,000 loan from the Development Bank of Wales and a £60,000 grant from Innovate UK, the mobile application has been developed to help people with communication difficulties to regain their ability to communicate, maintain relationships and re-integrate into the community. Cog-Neuro was first established by speech therapist Sheiladen Montero Aquino in 2012. She has now developed an application that will enhance speech therapy service for people with communication difficulties following a stroke, brain injury, and other progressive neurological disorders including Parkinson’s disease and Multiple Sclerosis.
25th March 2019
The number of active UK biotechnology businesses in the field of research and experimental development has soared by 65% in just over three years as the sector attracts record levels of funding, according to new analysis by investment manager Downing LLP.
20th March 2019
Belfast-based health tech company, Neurovalens, has secured one of the largest ever Series A investments generated by a Northern Irish technology company.
The company specialises in using neuroscience to solve everyday health issues.
The £4.6 million raise was led by London-based Wharton Asset Management along with Cambridge based IQ Capital. The round was also supported by Techstart Ventures, through its Invest NI-backed fund, The UU Fund, Co-Fund NI managed by Clarendon Fund Management, Beltrae Partners and the Angel CoFund.